Lexeo Therapeutics develops gene therapies that aim to treat inherited heart diseases in patients with genetic cardiomyopathies. It last closed at $2.96 on Nov 20, up 0.34% on the day. The next earnings report for LXEO is expected around Mon, Mar 29, 2027, after the close. For the quarter ended Sep 2026, LXEO reported EPS of -$0.43. Over its last 8 reports the stock moved an average of 10.8% the session after earnings. Over the last 12 months LXEO insiders bought $0 of stock on the open market and sold $739K, according to SEC Form 4 filings.
AI Auto Pilots
Is LXEO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LXEO.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on LXEOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
LXEO · as of the Nov 20 close · updated each morning
Downtrend
The stock is 2% below its 20 day and 9% below its 50 day average. It is 65% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 47). The nearest support is the Pivot S1 at $2.82, and the nearest resistance the 20 day average at $3.00.
Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 12.6%/day
Key levels
$10.9952 week high+271.3%
$4.88200 day average+64.9%
$3.97100 day average+34.1%
$3.2250 day average+8.8%
$3.17Pivot R1+7.1%
$3.12Swing high (Oct 22)+5.4%
$3.03Pivot+2.4%
$3.0020 day average+1.4%
$2.96Last close
$2.82Pivot S1−4.7%
$2.70Swing low (Nov 6)−8.8%
$2.5552 week low−13.9%
Indicators
RSI (14)
46.89
Middle of its range
Neutral
MACD
-0.07
Above its signal line
Bullish
Stochastic
15.8
Near the bottom of its range
Oversold
ADX (14)
22.1
Weak trend
Williams %R
-83.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-1.0
Oversold below −100, overbought above 100
Neutral
Rate of change
+2.4%
Change over 10 sessions
Bullish
ATR (14)
$0.37
Typical daily range, 12.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityNormal, 26.0%/day
Key levels
$10.9952 week high+271.3%
$4.88200 day average+64.9%
$3.97100 day average+34.1%
$3.2250 day average+8.8%
$3.17Pivot R1+7.1%
$3.12Swing high (Oct 22)+5.4%
$3.03Pivot+2.4%
$3.0020 day average+1.4%
$2.96Last close
$2.82Pivot S1−4.7%
$2.70Swing low (Nov 6)−8.8%
$2.5552 week low−13.9%
Indicators
RSI (14)
34.78
Weak, oversold below 30
Neutral
MACD
-0.72
Below its signal line
Bearish
Stochastic
12.5
Near the bottom of its range
Oversold
ADX (14)
24.0
Weak trend
Williams %R
-85.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-57.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−30.4%
Change over 10 sessions
Bearish
ATR (14)
$0.77
Typical daily range, 26.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for LXEO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how LXEO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow LXEO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for LXEOHow many large options trades hit LXEO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in LXEO in the last 90 days.
From SEC Form 4 filings by LXEO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LXEO is in one of them and how their past LXEO trades turned out.
Lexeo Therapeutics is a biotechnology company based in New York that develops gene therapies for inherited heart diseases. Its candidates are designed to deliver working copies of disease-linked genes to heart muscle cells. The lead programs target Friedreich ataxia cardiomyopathy and arrhythmogenic cardiomyopathy caused by PKP2 gene mutations, and the company is also developing candidates for other genetic heart conditions. Its target patients have genetic heart diseases with few or no approved treatments.